AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report second quarter 2024 financial results on Wednesday, August 14, 2024, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial re ...

AUSTIN, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the 2024 Society for Neuro-Oncology (SNO) / American Society for Clinical Oncology (ASCO) CNS Metastases Conference August 8-10, in Denver, Colorado. "This year's SNO/ASCO Metastases confer ...

The presentation will report data from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Session Clinical Trial Updates in Radionuclide Theranostics Investor Contact Charles Y. Huang, MBA Director of Capital Markets and Investor Relations Office: (202)-209-5751 | Direct (301)-728-7222 chuang@plustherapeutics.com Title Targeted Radiolabeled Nanoliposo ...

Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PLUS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 33-0827593 (Primary Standard Industrial Classification Code Number) Table of Contents As filed with the Securities and Exchange Commission on June 24, 2024 Registration No. 333-280061 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (I.R.S. Employer ...

As filed with the Securities and Exchange Commission on June 7, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PLUS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 33-0827593 (I.R.S. Employer Identification Number) 4200 Marathon Blvd., ...

Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary CPRIT was created by the Texas Legislature and approved by a statewide vote in 2 ...

About Plus Therapeutics Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply c ...

Core Viewpoint - Plus Therapeutics, Inc. has granted option awards to its new Director of Capital Markets and Investor Relations, Charles Huang, to incentivize his employment with the company [1][2]. Group 1: Option Awards Details - The approved option awards allow Mr. Huang to purchase up to 5,000 shares of the company's common stock [2]. - The options will vest over four years, with one-fourth vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments [2]. - The exercise price of the options is set at the closing price of the company's common stock on the grant date, May 8, 2024 [2]. Group 2: Alignment of Interests - The company believes that these equity grants create a strong alignment of interests between Mr. Huang and the shareholders [3]. - The equity awards were granted outside of the company's 2020 Incentive Plan but have terms consistent with that plan [3]. - A Form S-8 has been filed covering these equity awards [3]. Group 3: Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers [4]. - The company aims to enhance clinical outcomes for patients through a combination of image-guided local beta radiation and targeted drug delivery approaches [4]. - Plus Therapeutics has a pipeline of product candidates, with lead programs in recurrent glioblastoma and leptomeningeal metastases, and has established a supply chain through strategic partnerships [4].

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q1 2024 Earnings Conference Call May 15, 2024 5:00 PM ET Company Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice President and Chief Financial Officer Norman LaFrance - Senior Vice President and Chief Medical Officer Conference Call Participants Justin Walsh - Jones Trading Edward Woo - Ascendiant Capital Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Welcome to the Plus Therapeutics' First Quarter 2024 Res ...

Exhibit 99.1 Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus' clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line FORESEE clinical trial data Management to Host Conference Call May 15, 2024 at 5:00 p.m. ET AUSTIN, Texas ...